Q1 25 EPS
$2.77
BEAT +7.34%
Est. $2.58
Q1 25 Revenue
$21.89B
BEAT +1.48%
Est. $21.57B
vs S&P Since Q1 25
+15.2%
BEATING MARKET
JNJ +52.3% vs S&P +37.1%
Market Reaction
Did JNJ Beat Earnings? Q1 2025 Results
Johnson & Johnson opened 2025 with a convincing beat across the board, posting first-quarter adjusted EPS of $2.77 against a consensus of $2.58, a 7.34% beat, while revenue of $21.89 billion edged past estimates by 1.48% and grew 2.4% year-over-year.… Read more Johnson & Johnson opened 2025 with a convincing beat across the board, posting first-quarter adjusted EPS of $2.77 against a consensus of $2.58, a 7.34% beat, while revenue of $21.89 billion edged past estimates by 1.48% and grew 2.4% year-over-year. The headline driver was a surging oncology franchise within Innovative Medicine, where DARZALEX alone contributed $3.24 billion in sales, up 20.3%, helping offset an approximately 810 basis point headwind from STELARA biosimilar erosion. MedTech added $8.02 billion, lifted by cardiovascular strength including the newly acquired Shockwave platform. For investors watching the dividend champion closely, J&J also announced a 4.8% dividend increase, its 63rd consecutive year of raises, alongside a commitment to more than $55 billion in U.S. Investment. Looking ahead, the company maintained its adjusted EPS guidance of $10.50–$10.70 for full-year 2025, absorbing tariff costs and acquisition dilution while integrating Intra-Cellular Therapies' CAPLYTA into its growing neuroscience portfolio.
Key Takeaways
- • DARZALEX worldwide sales grew 20.3% to $3.2B driven by strong demand in oncology
- • CARVYKTI worldwide sales more than doubled to $369M
- • TREMFYA grew 18.2% to $956M with Crohn's disease approval expanding addressable market
- • SPRAVATO grew 41.9% to $320M in neuroscience
- • XARELTO grew 33.3% to $690M in cardiovascular
- • MedTech Cardiovascular grew 16.4% driven by Abiomed and Shockwave acquisition
- • STELARA declined 33.7% to $1.6B representing ~810 basis points headwind from biosimilar competition
- • U.S. sales grew 5.9% while international declined 1.8% due to currency headwinds
JNJ YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
JNJ Revenue by Segment
With YoY comparisons, source: SEC Filings
JNJ Revenue by Geography
With YoY comparisons, source: SEC Filings
“The power of Johnson & Johnson's uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance.”
— Joaquin Duato, Q1 2025 Earnings Press Release
JNJ Earnings Trends
JNJ vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
JNJ EPS Trend
Earnings per share: estimate vs actual
JNJ Revenue Trend
Quarterly revenue: estimate vs actual
JNJ Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.70 | — | $24.06B | +1.89% |
| Q4 25 BEAT FY | $2.46 | $2.46 | +0.00% | $24.56B | — |
| FY Full Year | $10.80 | $10.79 | -0.13% | $94.19B | +0.46% |
| Q3 25 BEAT | $2.76 | $2.80 | +1.49% | $23.99B | +1.00% |
| Q2 25 BEAT | $2.68 | $2.77 | +3.43% | $23.74B | +3.88% |
| Q1 25 BEAT | $2.58 | $2.77 | +7.34% | $21.89B | +1.48% |